All In Biotech

Drug Trial Radar · NCT06272149

An Exploratory Clinical Trial of VGN-R08b in Patients With Type II Gaucher Disease

An Exploratory Clinical Trial to Evaluate the Tolerability and Safety of VGN-R08b Via Intracerebroventricular Injection in Patients With Type II Gaucher Disease

Last checked: Nov 20, 2026Latest source record: Feb 22, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

6

Planned (sponsor's estimate)

Start

Mar 1, 2023

Primary completion

Jan 15, 2025

Study completion Feb 28, 2029

Sponsor

Sponsor type
Academic, hospital or other
Collaborators
Shanghai Vitalgen BioPharma Co., Ltd.
First posted
Feb 22, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Early phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 0 months, up to 24 months
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This exploratory trial is to prove the tolerability and safety of VGN-R08b to treat infants with type II Gaucher disease.

Conditions

  • Type II Gaucher Disease

Interventions

  • VGN-R08bDrug

    VGN-R08b is a kind of Gene therapy with adeno-associated virus (AAV) serotype 9 (AAV9) driven human GBA1 being injected directly into intracerebroventricular.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Adverse Events (AEs), Serious Adverse Events (SAEs)Time frame: Week 52

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Xinhua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine

    Shanghai, Shanghai Municipality, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.